Brief: Candel Therapeutics Reports Q4 Loss Per Share Of $0.18

Candel Therapeutics

30/03/2023 14:41

March 30 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS
    * CANDEL THERAPEUTICS INC - EXPECTS TO ANNOUNCE CLINICAL
TRIAL
DATA FROM MULTIPLE ONCOLOGY PROGRAMS IN SECOND HALF OF 2023
    * CANDEL THERAPEUTICS INC - EXTENDS CASH RUNWAY INTO Q2 OF
2024
    * CANDEL THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF
DECEMBER 31, 2022 WERE $70.1 MILLION
    * CANDEL THERAPEUTICS - CASH AND CASH EQUIVALENTS AS OF DEC
31,
2022 REFLECTED RECEIPT OF $20.0 MILLION FROM TERM LOAN WITH
SILICON VALLEY BANK IN FEB 2022

Source text for Eikon:  ID:nGNX5x8KBp 
Further company coverage:  CADL.O 

 ((Reuters.Briefs@thomsonreuters.com;))